Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Myrcludex B + PEG-IFN vs PEG-IFN in Chronic Hepatitis D (MYR 203)
NCT02888106Phase 2Completed
- Sponsor
- Hepatera
- Start
- Apr 2016
- Primary completion
- Nov 2019
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bulevirtide in hepatitis D (HDV), sponsored by Hepatera. Primary endpoint: Percentage of Patients With Negative HDV RNA by PCR at 72 weeks. Started Apr 2016; status: completed.
02
Drugs
bulevirtide
03
Conditions
hepatitis D (HDV)
Beyond the preview
Go deeper on NCT02888106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02888106.